Condensate Therapeutics for Cancers

CD BioSciences is dedicated to developing disease-targeted condensate therapeutics to advance the field of refractory diseases. Here, we offer condensate therapeutics for cancers, offering new hope for the treatment of cancers.

Condensate Research Offers New Hope for the Treatment of Cancers

Cancer is characterized by uncontrolled cell proliferation, which is driven by dysregulated oncogene or oncogene activity due to genomic instability, dysregulated gene expression, or protein degradation. Cancer cells are also highly resistant to stressful conditions and readily adapt to new environments upon metastasis. These disease phenotypes are associated with the function of various cohesions. The formation and regulation of biomolecular condensates are intricately linked to cancer formation and progression. New insights from condensate studies herald a profound shift in our understanding of cancer cell dysregulation and facilitate the development of new therapies. However, many challenges remain to be overcome, including the development of molecules capable of selectively targeting different phase-separated condensates in the same cellular environment. Furthermore, differential drug segregation in condensates increases the likelihood of drug resistance through mutations that alter phase segregation.

Fig. 1. Different approaches for targeting biomolecular condensates in cancer. (Cai D, et al, 2021)

Our Solutions

CD BioSciences offers comprehensive services to analyze abnormally altered biomolecular condensates in cancer with the aim of investigating the role of LLPS in cancer and developing drug candidates that target LLPS regulation to combat tumorigenesis. CD BioSciences recognizes the great potential of targeting biomolecular condensates as a novel therapeutic approach for cancer treatment. Our innovative platform leverages the unique properties of condensates to develop targeted therapies that specifically disrupt or modulate the function of these compartments.

Our experts are dedicated to developing druggable biomolecular condensates for cancer therapy. We offer the following three potential condensate-based cancer therapeutic strategies:

• Targeting Dysregulated Condensates
  We offer a proximity-based proteomics approach to find and target the driver components associated with cancer-related biomolecular condensates, and then knock down the different related components to determine the impact on condensate formation.
• Designing Condensates-disrupting Drugs
  Our experts design and develop small molecule drugs to selectively disrupt dysregulated condensates in cancer cells. We utilize state-of-the-art computational methods and high-throughput screening approaches to identify drug candidates that specifically target key components or interactions of condensate formation. These drugs are designed to disrupt the assembly and stability of oncogenic condensates, thereby inhibiting tumor growth and metastasis.
• Adding Drugs that Directly Break Down into Specific Types of Condensates
  We offer artificial intelligence-assisted large-scale image-based screening methods to identify or select drugs that can disassemble into specific types of condensates to modify their properties in the live cellular environment.

CD BioSciences is dedicated to advancing the field of condensation therapy for cancer treatment. We continue to explore the role of biomolecular condensates in various cancer types and their potential as therapeutic targets. By combining our expertise in condensation biology, drug discovery, and clinical development, we strive to accelerate the translation of condensate therapeutics from the laboratory to the clinic. If you are interested in our solutions, please contact us for more information.